CalciMedica, Inc. (CALC)

NASDAQ: CALC · Real-Time Price · USD

5.85

+0.52 (9.76%)

At close: Jan 9, 2026, 4:00 PM EST

5.96

+0.11 (1.88%)

After-hours: Jan 9, 2026, 5:06 PM EST

CalciMedica Employees

CalciMedica had 14 employees as of December 31, 2024. The number of employees increased by 2 or 16.67% compared to the previous year.

Employees

14

Change

2

Growth

16.67%

Revenue / Employee

n/a

Profits / Employee

-$1,647,143

Market Cap

84.30M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	2	16.67%
Dec 31, 2021	12	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

CALC News

2 months ago - CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PRNewsWire
2 months ago - CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension - PRNewsWire
2 months ago - CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025 - PRNewsWire
3 months ago - CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™ - PRNewsWire
4 months ago - CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
5 months ago - CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PRNewsWire
6 months ago - CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - PRNewsWire
7 months ago - CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure - PRNewsWire